Biomarkers for diagnosing non-alcoholic steatohepatitis (nash) or hepatocellular carcinoma (hcc)
AssigneeVenn Biosciences Corporation
InventorsPrasanna Ramachandran, Gege xu
Life of this patent
Estimating the term…
Loading patent…
AssigneeVenn Biosciences Corporation
InventorsPrasanna Ramachandran, Gege xu
Estimating the term…
Embodiments described herein generally relate to technologies for analyzing peptide structures for diagnosing and/or treating a disease state advancing through a disease progression. A non-limiting example of a method relating to the technologies described in the subject application may include receiving peptide structure data corresponding to the biological sample obtained from the subject, identifying a peptide structure profile, and diagnosing a disease state within a disease progression. The example may further include generating a diagnosis output relating to the disease state. In at least some cases, the peptide structure profile may include glycosylated peptides, aglycosylated peptides, or both.
A method of classifying a biological sample with respect to a plurality of states associated with fatty liver disease (FLD) progression, the method comprising:
A method of training a model to diagnose a subject with one of a plurality of states associated with fatty liver disease (FLD) progression, the method comprising:
A method of detecting a presence of one of a plurality of states associated with fatty liver disease (FLD) progression in a biological sample, the method comprising:
Dependencies are inferred from the claim text.